A review paper has been published in the journal Drug Discovery Today discussing the use of systems biology approaches for studying neurodegenerative diseases including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). Neurodegenerative diseases (NDDs), such as Alzheimer’s (AD) and Parkinson’s (PD), are among the leading causes of lost years of healthy life and exert a great strain on public healthcare systems. Despite being first described more than a century ago, no effective cure exists for AD or PD. Although extensively characterized at the molecular level, traditional neurodegeneration research remains marred by narrow-sense approaches surrounding amyloid β (Aβ), tau, and α-synuclein (α-syn). A systems biology approach enables the integration of multi-omics data and informs discovery of biomarkers, drug targets, and treatment strategies. They presented a comprehensive timeline of high-throughput data collection, and associated biotechnological advancements and computational analysis related to AD and PD.
A review article about neurodegenerative diseases
ScandiBio Therapeutics → News → A review article has been published about the use of AI-based systems biology for drug development to treat neurodegenerative diseases